Leukocyte-Derived Microparticles as Proinflammatory Mediators in Atherosclerosis∗  by Wang, Jian-Guo et al.
Journal of the American College of Cardiology Vol. 62, No. 16, 2013
 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.04.054EDITORIAL COMMENT
Leukocyte-Derived
Microparticles as
Proinflammatory Mediators
in Atherosclerosis*
Jian-Guo Wang, PHD,y Elena Aikawa, MD, PHD,yz
Masanori Aikawa, MD, PHDyz
Boston, Massachusetts
Emerging evidence has highlighted the role of extracellular
vesicles in cell-to-cell communication between neighboring
cells or remote organs and as biomarkers (1). According to
a recent proposal for a consensus nomenclature by the Inter-
national Society for Extracellular Vesicles, extracellular vesicles
are classiﬁed into 3 biologically distinct entities based on the
size and intracellular mechanisms: 1) ectosomes; 2) exosomes;
and 3) apoptotic bodies (2). Ectosomes, also known as
microparticles (MPs) or microvesicles, are large extracellular
vesicles (diameter 50 nm to 1000 nm), and are surrounded bySee page 1436a phospholipid bilayer. MPs are released into extracellular
space or circulation by direct budding from the plasma
membrane from multiple lineages of activated cells, including
platelets, endothelial cells, granulocytes, monocytes, macro-
phages, and lymphocytes. Exosomes, small membranous
vesicles of endocytic origin (40 nm to 100 nm), are generated
by exocytosis of multivesicular bodies. Apoptotic bodies are
released from fragmented apoptotic cells and are 50 nm to
5000 nm in diameter. Yet another category is comprised of ma-
trix vesicles, small membranous structures (30 nm to 300 nm)
surrounded by a lipid bilayer. Matrix vesicles are released from
living osteoblasts and chondrocytes, and promote bone and
cartilage mineralization. Recent studies have demonstrated
that matrix vesicles derived from smooth muscle cells and
macrophages induce ectopic cardiovascular calciﬁcation (3,4).*Editorials published in the Journal of the American College of Cardiology reﬂect the
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In healthy individuals, leukocyte-derived MPs (LMPs)
represent a minor portion (<10%) of the total MP pop-
ulation in blood (5). Plasma levels of LMPs signiﬁcantly
increase in patients with cardiovascular and metabolic
disorders, including atherosclerosis, venous thromboembo-
lism, hypertension, and diabetes mellitus (6,7). Plasma
LMPs detected by immunocapture assay positively correlate
with plaque burden in asymptomatic patients with subclin-
ical atherosclerosis (8).
Human atherosclerotic plaques contain MPs, which
originate from leukocytes, erythrocytes, smooth muscle cells,
and endothelial cells (9). LMPs harbor cell-speciﬁc anti-
gens such as CD11b, CD66b, and CD15, which allow
their detection by ﬂow cytometry. Furthermore, LMPs
contain bioactive proteins such as interleukin 1b, CD40
ligand, major histocompatibility complex class I and II,
and intercellular adhesion molecule (ICAM)-1, which
induce leukocyte activation, endothelial cell proliferation,
intraplaque neovascularization, and monocyte adhesion and
migration (10–13). Plaque LMPs also contain various
members of the matrix metalloproteinase (MMP) family,
including the potent collagenases MMP-1, MMP-8, and
MMP-13 (14), and may induce plaque instability. In addi-
tion, these LMPs are highly procoagulant because of the
exposure of anionic phosphatidylserine and tissue factor
(9,15). These lines of evidence suggest that plaque LMPs
contribute to various stages of plaque pathogenesis,
from initiation to acute onset of acute thrombotic compli-
cations (Fig. 1).
Multiple technologies, including ﬂow cytometry, electron
microscopy, dynamic light scattering, atomic force micros-
copy, and nanoparticle tracking analysis, can detect MPs
(16,17). Flow cytometry can quantify MPs in a high-
throughput fashion and determine the cellular origin of
MPs in plasma, and is thus widely used in clinical settings.
But conventional ﬂow cytometry only detects a small portion
of the MPs ranging in diameter from 300 nm to 1000 nm,
due to its inherent limitation of forward scatter sensitivity.
Newly developed high-sensitivity ﬂow cytometry has
improved resolution and lowered background noise, which
allows the enumeration of previously undetectable small MPs
(diameter 100 nm to 300 nm). In a validation study on
platelet-free plasma from patients with stable coronary
disease, high-sensitivity ﬂow cytometry could detect 8- to
20-fold more MPs than conventional ﬂow cytometry (18).
In this issue of the Journal, Sarlon-Bartoli et al. (19)
analyzed levels of LMPs using high-sensitivity ﬂow cytom-
etry in plasma from 42 patients with high-grade (>70%)
carotid stenosis. They found that median levels of LMPs,
displayed with CD11bCD66bþ or CD15þ labeling, were
signiﬁcantly higher in patients with unstable plaque
compared to patients with stable plaque. Most importantly,
levels of CD11bCD66bþ LMPs independently associated
with plaque instability in all patients as well as in the group of
Figure 1 Potential Roles of Extracellular Vesicles in Atherogenesis and Remote Organ Crosstalk
In atherosclerotic plaques, cell types including macrophages and smooth muscle cells (SMC) generate microparticles (MPs, or matrix vesicles). Macrophage-derived MPs
contain proinﬂammatory molecules (e.g., interleukin 1bCD40 ligand) and may enhance the atherogenic milieu. They may promote endothelial proliferation and angiogenesis
(mediated by CD40 ligand), enhance monocyte adhesion and migration by delivering intercellular adhesion molecule (ICAM)-1 to endothelial cells, and induce matrix degradation
and plaque instability through various proteolytic enzymes (e.g., matrix metalloproteinase [MMP]-collagenases). Macrophage-derived MPs contain P-selectin ligands (e.g., CD15,
P-selectin glycoprotein ligan [PSGL]-1), tissue factor, and phosphatidylserine, and may promote atherothrombosis at the site of plaque rupture. Matrix vesicles released from
macrophages and SMC contribute to ectopic vascular calciﬁcation. These MPs and matrix vesicles may interact with their parental cells and induce inﬂammation and apoptosis
and amplify the release of MPs. In circulating blood, LMPs may originate from activated monocytes and/or atherosclerotic plaques by undeﬁned mechanisms. The LMPs contain
multiple receptors (CD15, PSGL-1, and ICAM-1) that facilitate their docking with activated endothelium in remote arteries and veins. In addition, LMPs may be taken up by
macrophages and endothelial cells in the spleen, liver, and lung and have a potential impact on these remote organs.
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1443asymptomatic patients by a multivariate analysis. To
strengthen the study, Sarlon-Bartoli et al. (19) applied
conventional and high-sensitivity ﬂow cytometry to analyze
LMPs in plasma samples in the same study cohort.
Consistent with a previous report (18), high-sensitivity ﬂow
cytometry detected 13-fold more LMPs (CD11bCD66bþ)
in the whole population and 11-fold more in the asymp-
tomatic group with unstable plaque (19). In contrast,
conventional ﬂow cytometry identiﬁed no statistically
signiﬁcant differences in LMP numbers in patients with
stable plaques and in patients with unstable plaques (19).
These results support the concept that including the small-
sized MP subpopulation in the plasma provides more bio-
logical information in clinical studies.
Earlier studies found a trend of more LMPs presenting
in plaque from symptomatic patients compared with an
asymptomatic group using conventional ﬂow cytometry
analysis (9,11). Yet the key question about whether elevated
LMPs in these studies, including the study by Sarlon-Bartoli
et al. (19), indeed originated from atherosclerotic plaques,
remains unanswered. Quantifying the levels of LMPs in
both plasma and plaque tissues in the same symptomatic andasymptomatic patients using high-sensitivity ﬂow cytometry,
and correlating these 2 parameters, will be crucial. Such
analyses may not only validate clinical signiﬁcance of plasma
LMPs as a biomarker of cardiovascular risk, but also may
identify the origin of circulating LMPs.
Macrophages produce approximately 60% of the LMPs in
atherosclerotic plaques (9). Conventional understanding
holds that macrophages and foam cells generate these MPs
during apoptosis. Recent studies have shown that living
monocytes/macrophages also release MPs upon activation by
different stimuli, including lipopolysaccharide (10), cigarette
extract (20), high-density lipoprotein cholesterol (21), and
calcium/phosphate (4). Stimulation of P2X purinoceptor 7
(P2X7R) by adenosine triphosphate can induce the release of
MPs from microglia (resident macrophages in the brain)
through the activation of p38 MAPK and acid sphingo-
myelinase (22). The P2X7R-mediated signaling also regu-
lates the formation of procoagulant tissue factor-positive
MPs from macrophages and smooth muscle cells, and plays
a signiﬁcant role in the FeCl3-induced carotid artery
thrombosis model (23). Another in vitro study demonstrated
that activation of Toll-like receptors (e.g., TLR-3, TLR-4)
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1444induces MP release from mouse macrophages, mediated by
inducible nitric oxide synthase (24). We demonstrated that
CD68-positive macrophages release matrix vesicles in vivo
and that calcium/phosphate stimulation induces vesicle
release from cultured primary human macrophages (4).
Although shared and distinctive features between small
LMPs, exosomes, and matrix vesicles need to be investi-
gated, these results suggest a potential role of macrophage-
derived extracellular vesicles in cardiovascular calciﬁcation.
MPs, as subcellular vectors, can transmit biological
information and mediate cell-to-cell communication. Several
studies suggest that plaque LMPs mediate the interplay
between various cells within atherosclerotic vascular lesions
(11–14), and may mediate the remote organ crosstalk by
traveling through the circulating blood. The LMPs contain
tissue factor and P-selectin glycoprotein ligand (PSGL)-1,
interact with P-selectin on activated platelets, and play an
important role in thrombus formation in animal models of
venous thrombosis (25,26). Elevated levels of circulating
tissue factor–bearing MPs, likely derived from hematopoietic
myeloid cells, appear to increase ﬁbrin deposition at the laser-
injured site in arteries of hypercholesterolemic mice (27).
Plaque LMPs bearing P-selectin ligands (e.g., CD15,
PSGL-1) and tissue factor (15) may enter the circulation.
These procoagulant LMPs may bind to P-selectin expressed
on activated platelets or P-, E-selectin on activated endo-
thelium, and potentially contribute to various pathologic
processes including thrombosis in remote vessels (Fig. 1).
How MPs derived from plaque macrophages enter the blood
circulation, however, is not clear.
Exogenous MPs are taken up by macrophages (phago-
cytosis) and endothelial cells in multiple organs, including
spleen, liver, kidney, and lung (28). But the clearance of
LMPs and endogenous MPs remain incompletely under-
stood. This process may involve the interaction of phos-
phatidylserine on LMPs with integrin avb3 expressed on
macrophages, or activated endothelial cells with lactadherin
or developmental endothelial locus-1 (29) serving as
a bridging molecule (28). In this scenario, LMPs derived
from atherosclerotic plaques may impact remote organs
where their clearance occurs (Fig. 1).
Although numerous in vitro studies have suggested that
LMPs contribute to plaque development and progression in
atherosclerosis, in vivo evidence for their roles remain scant.
Administration of MPs, derived from human monocytic
THP-1 cells, signiﬁcantly increases the inﬁltration of
monocytes and T cells into the vessel wall and promotes
plaque formation in high-fat–fed ApoE-null mice (30).
Determining the effect of plaque-derived LMPs on lesion
formation in experimental atherosclerosis will be worthwhile.
In addition, MPs generated from different macrophage
subtypes in plaques, such as M1 and M2, may have distinct
properties (e.g., atherogenic vs. atheroprotective).
The study by Sarlon-Bartoli et al. (19) highlights the
clinical signiﬁcance of circulating LMPs as a promising
biomarker associated with plaque vulnerability in patientswith high-grade carotid stenosis. The question of whether
plasma levels of LMPs predict the occurrence of neurological
events in asymptomatic patients warrants large-scale
prospective studies. The potential function of LMPs (e.g.,
macrophage-derived MPs) generated in atherosclerotic pla-
ques also deserves further investigation using well-deﬁned
animal models. Furthermore, understanding the cellular
origin and biology of increased levels of MPs will validate
their signiﬁcance as biomarkers, and provide important
insight into the intriguing possibility that LMPs mediate
complex crosstalk between remote organs in normal homeo-
stasis and disease processes.
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